Immuno-oncology has seen some striking clinical advances in the 10 years since the approval of the first therapeutic cancer vaccine, but it’s a field that doesn’t stand still. With the majority of solid tumors predicted to be treated by immuno-oncology medicines by 2050, now is an ideal time to take stock of the key trends in the area and prepare for its future. Our new white paper takes stock of where the pharmaceutical industry is today and looks at how it can get to where it needs to be tomorrow.
